Screener
Axsome Therapeutics AXSM Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:CommonStockValue.
The source filing: Axsome Therapeutics’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 5:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-204274
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Total liabilities | 659,020 | 601,510 |
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value per share (10,000,000 shares authorized, none issued and outstanding) | — | — |
| Common stock, $0.0001 par value per share (150,000,000 shares authorized, 51,420,445 and 50,882,766 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively) | 5 | 5 |
| Additional paid-in capital | 1,425,085 | 1,394,251 |
| Accumulated deficit | (1,370,503) | (1,305,961) |
| Total stockholders’ equity | 54,587 | 88,295 |
| Total liabilities and stockholders’ equity | $713,607 | $689,805 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Axsome Therapeutics's common stock?
- Axsome Therapeutics (AXSM) reported common stock of $5K in Q1 2026.
- How has Axsome Therapeutics's common stock changed year-over-year?
- Axsome Therapeutics's common stock decreased by 0.0% year-over-year, from $5K to $5K.
- What is the long-term trend for Axsome Therapeutics's common stock?
- Over 5 years (2020 to 2025), Axsome Therapeutics's common stock has grown at a 6.0% compound annual growth rate (CAGR), from $3.74K to $5K.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about Axsome Therapeutics's common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude